Tactile Medical Announces Publication of Expert Opinion Consensus Statement in Phlebology Recommending the Use of Pneumatic Compression for Lymphedema
Tactile Systems Technology (Nasdaq: TCMD) announced a consensus statement highlighting the treatment of lymphedema, particularly secondary to chronic venous insufficiency (CVI). Published in Phlebology: The Journal of Venous Disease, the statement received endorsements from three independent professional societies. Key points include that pneumatic compression is recommended for lymphedema patients, and 92% of experts support its use. CEO Dan Reuvers emphasized the importance of addressing the estimated 20 million undiagnosed lymphedema cases in the U.S.
- Consensus among experts endorsing pneumatic compression therapy for lymphedema.
- 92% agreement from the panel on the recommendation of sequential pneumatic compression.
- Focus on addressing the significant number of undiagnosed lymphedema cases, which could expand market potential.
- None.
Consensus that Patients with Chronic Venous Insufficiency Should be Considered Lymphedema Patients
MINNEAPOLIS, June 07, 2022 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases at home, today announced the publication of an expert opinion consensus statement. Three independent societies’ consensus endorsements were published in peer-reviewed Phlebology: The Journal of Venous Disease. The statement affirmed that pneumatic compression should be recommended as a treatment for lymphedema, including lymphedema which is secondary to chronic venous insufficiency (“CVI”).
The Delphi methodology was used to assess experts’ opinions on the available literature related to lymphedema, to provide consensus guidance on diagnosis and patient treatment pathways for this commonly overlooked condition. Experts from the American Venous Forum, American Venous and Lymphatic Society and Society for Vascular Medicine evaluated a number of clinical considerations around risk factors, diagnosis and evaluation, and treatment of lymphedema. After analyzing the available research and data, the panel of experts reached consensus on various factors, including:
- Cancer, infection, chronic venous disease, and surgery are all risk factors for secondary lymphedema.
- Patients with CVI, clinical stages 3-6, should be treated as lymphedema patients.
- Clinical examination is sufficient for the diagnosis of lymphedema.
- Regular use of compression garments reduces progression of lymphedema.
92% of the panel agreed that sequential pneumatic compression should be recommended for lymphedema patients.
“Recommended use of pneumatic compression achieved the highest level of consensus, and it is encouraging to see such uniformity among three independent professional societies,” said Kristie Burns, Senior Vice President, Marketing and Clinical Affairs of Tactile Medical.
Dan Reuvers, President and Chief Executive Officer of Tactile Medical, added, “With 20 million lymphedema cases believed to be undiagnosed in the U.S., Tactile Medical is committed to serving patients and bringing more attention to this underdiagnosed and underserved community.”
The publication in Phlebology: The Journal of Venous Disease, can be accessed via the following website: click here
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the impacts of the COVID-19 pandemic on the Company’s business, financial condition and results of operations and the Company’s inability to mitigate such impacts; the adequacy of the Company’s liquidity to pursue its business objectives; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; the effects of current and future U.S. and foreign trade policy and tariff actions; or the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company undertakes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
FAQ
What is the significance of the recent consensus statement published by Tactile Systems Technology?
What percentage of experts endorsed pneumatic compression for lymphedema?
How many undiagnosed lymphedema cases are estimated in the U.S.?
In which journal was the consensus statement published?
